Assessment of an in-house IgG ELISA targeting SARS-CoV-2 RBD: Applications in infected and vaccinated individuals

Autor(es):Mostrar menos -

da Costa, Hernan Hermes Monteiro ; Silva, Valeria Oliveira ; Amorim, Gustavo Carvalho ; Guereschi, Marcia Grando ; Sergio, Luciana Marciano ; Gomes, Carlos Henrique Rodrigues ; Hong, Marisa Ailin ; de Oliveira, Elaine Lopes ; Brigido, Luis Fernando de Macedo ; Lindoso, Jose Angelo Lauletta ; Prudencio, Carlos Roberto

• Tipo de documento: Artigo Científico
• Fonte: JOURNAL OF IMMUNOLOGICAL METHODS; v. 530, p. 12-pg., 2024-05-22.

Resumo

The study evoluated an in-house Spike Receptor Binding Domain Enzyme-Linked Immunosorbent Assay (RBDIgG-ELISA) for detecting SARS-CoV-2 IgG antibodies in infected and vaccinated individuals. The assay demonstrated a sensitivity of 91%, specificity of 99.25%, and accuracy of 95.13%. Precision and reproducibility were highly consistent. The RBD-IgG-ELISA was able to detect 96.25% of Polymerase chain reaction (PCR) confirmed cases for SARS-CoV-2 infection, demonstrating positive and negative predictive values of 99,18% and 91,69%, respectively. In an epidemiological survey, ELISA, lateral flow immunochromatographic assay (LFIA), and electrochemiluminescence immunoassay (ECLIA) exhibited diagnostic sensitivities of 68.29%, 63.41%, and 70.73%, respectively, along with specificities of 82.93%, 80.49%, and 80.49%, respectively. Agreement between RBD-IgG-ELISA/PCR was moderate (k index 0.512). However, good agreement between different assays (RBDIgG-ELISA/LFIA k index 0.875, RBD-IgG-ELISA/ECLIA k index 0.901). Test performance on individuals' samples were inferior due to seroconversion time and chronicity. The IgG-RBD-ELISA assay demonstrated its effectiveness in monitoring antibody levels among healthcare professionals, revealing significant differences both before and after the administration of the third vaccine dose, with heightened protection levels observed following the third dose in five Coronavirus disease (COVID-19) vaccine regimens. In conclusion, the RBD-IgG-ELISA exhibits high reproducibility, specificity, and sensitivity, making it a suitable assay validated for serosurveillance and for obtaining information about COVID-19 infections or vaccinations. (AU)

• Processo FAPESP: 23/13212-8 - Avaliação da resposta imune humoral após a vacina bivalente de mRNA contra o SARS-Cov-2 por meio da técnica de PhIP-Seq
• Beneficiário: Carlos Roberto Prudencio
• Modalidade de apoio: Auxílio à Pesquisa - Regular
• Processo FAPESP: 21/11936-3 - Centro de Ciência Translacional e Desenvolvimento de Biofármacos
• Beneficiário: Benedito Barraviera
• Modalidade de apoio: Auxílio à Pesquisa - Centros de Ciência para o Desenvolvimento
• Processo FAPESP: 23/06453-9 - Construção e seleção de uma biblioteca de anticorpos monoclonais scFv contra a proteína spike de variantes de preocupação do SARS-CoV-2 pela tecnologia de Phage Display
• Beneficiário: Carlos Henrique Rodrigues Gomes
• Modalidade de apoio: Bolsas no Brasil - Programa Capacitação - Treinamento Técnico
• Processo FAPESP: 22/05566-1 - Construção e seleção de uma biblioteca de anticorpos monoclonais scFv contra a proteína spike do SARS-CoV-2 pela tecnologia de Phage Display
• Beneficiário: Hernan Hermes Monteiro da Costa
• Modalidade de apoio: Bolsas no Brasil - Doutorado